Ondas Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Ondas Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.73M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $7.19M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $15.69M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $2.13M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.91M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $2.16M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $320.4K | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $190.0K | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $274.4K | Mar 19, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.16M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $345.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $6.38M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $1.11M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.10M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $927.7K | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $241.3K | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $150.7K | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $194.6K | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | ($6.9K) | Mar 28, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($132.24M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($38.01M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($44.84M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($73.24M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($15.02M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($13.48M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($19.39M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($12.10M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($3.02M) | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | ($34.6K) | Mar 28, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($58.38M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($34.61M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($39.73M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($69.43M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($17.97M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($11.52M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($15.37M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($8.44M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($2.39M) | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | ($34.6K) | Mar 28, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.88M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $12.48M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $17.15M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $24.04M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $5.80M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $3.59M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $5.42M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $3.08M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.00M | Mar 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($38.75M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($33.47M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($34.02M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($37.96M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($16.90M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($7.53M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($14.66M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($8.52M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($2.63M) | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | ($29.0K) | Mar 28, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.03M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.64M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $211.0K | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $2.88M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $923.7K | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $8.6K | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $77.9K | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $544.2K | Mar 13, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.13B | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $109.62M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $92.16M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $97.95M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $117.44M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $28.51M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $4.26M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $2.66M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $717.6K | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $5.7K | Mar 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $661.23M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $73.68M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $47.11M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $39.72M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $5.21M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $13.43M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $16.69M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $17.55M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $8.64M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $60.5K | Mar 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $437.81M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $16.58M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $33.14M | Mar 12, 2025 |
| FY2024 | Dec 31, 2022 | $58.22M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $112.23M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $15.08M | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | ($12.43M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2018 | ($14.88M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | ($7.92M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | ($4.91M) | Mar 19, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $251.81M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $27.75M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $27.75M | Mar 12, 2025 |
| FY2024 | Dec 31, 2022 | $25.61M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $45.03M | Apr 1, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($368.39M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($236.37M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($198.36M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($153.52M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($80.27M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($65.25M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($51.77M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($32.38M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($20.28M) | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | ($55.1K) | Mar 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $550.74M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $29.96M | Mar 30, 2026 |
| FY2022 | Dec 31, 2022 | $29.78M | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | $40.82M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $26.06M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $2.15M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $1.13M | Mar 13, 2020 |
| FY2019 | Dec 31, 2017 | $456.0K | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $45.2K | Mar 19, 2019 |
| FY2017 | Dec 31, 2015 | $5.2K | Mar 28, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $300.0K | Mar 12, 2025 |
| FY2020 | Dec 31, 2020 | $666.1K | Mar 8, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 14, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 14, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 380.76M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 93.17M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 61.94M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | 44.11M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 40.99M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 26.54M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | 19.76M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | 50.46M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | 16.80M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | 3.00M | Mar 28, 2018 |